A review of data and expert opinion from European Multidisciplinary Cancer Congress (EMCC) 2011: Dr Chris Parker and Dr Per-Anders Abrahamsson discuss the release of information on three new drugs designed to fight against castration resistant prostate cancer. The three drugs Sipuleucel-t provenge, Cabazitaxel and abiraterone bode well given that until now little progress has been made to fight this type of cancer. Dr Parker and Dr Per-Anders Abrahamsson discuss the potential of each drug and the timeline for trials.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).